VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2015 | Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and acalabrutinib (ACP-196), target chronic lymphocytic leukemia (CLL) cells and the common side-effects experienced by these drugs.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter